Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Combination therapy with angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinuria; however, its safety and effect on the progression of kidney disease are uncertain. Methods We provided losartan (at a dose of 100 mg per day) to patients with type 2 diabetes, a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 300, and an estimated glomerular filtration rate (GFR) of 30.0 to 89.9 ml per minute per 1.73 m(2) of body-surface area and then randomly assigned them to receive lisinopril (at a dose of 10 to 40 mg per day) or placebo. The primary end point was the first occurrence of a change in the estimated GFR (a decline of ≥ 30 ml per minute per 1.73 m(2) if the initial estimated GFR was ≥ 60 ml per minute per 1.73 m(2) or a decline of ≥ 50% if the initial estimated GFR was <60 ml per minute per 1.73 m(2)), end-stage renal disease (ESRD), or death. The secondary renal end point was the first occurrence of a decline in the estimated GFR or ESRD. Safety outcomes included mortality, hyperkalemia, and acute kidney injury. Results The study was stopped early owing to safety concerns. Among 1448 randomly assigned patients with a median follow-up of 2.2 years, there were 152 primary end-point events in the monotherapy group and 132 in the combination-therapy group (hazard ratio with combination therapy, 0.88; 95% confidence interval [CI], 0.70 to 1.12; P=0.30). A trend toward a benefit from combination therapy with respect to the secondary end point (hazard ratio, 0.78; 95% CI, 0.58 to 1.05; P=0.10) decreased with time (P=0.02 for nonproportionality). There was no benefit with respect to mortality (hazard ratio for death, 1.04; 95% CI, 0.73 to 1.49; P=0.75) or cardiovascular events. Combination therapy increased the risk of hyperkalemia (6.3 events per 100 person-years, vs. 2.6 events per 100 person-years with monotherapy; P<0.001) and acute kidney injury (12.2 vs. 6.7 events per 100 person-years, P<0.001). Conclusions Combination therapy with an ACE inhibitor and an ARB was associated with an increased risk of adverse events among patients with diabetic nephropathy. (Funded by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; VA NEPHRON-D ClinicalTrials.gov number, NCT00555217.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given that diastolic heart disease develops early in T2D and the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of HF, the use of an ACE inhibitor or ARBs could be considered early in the treatment of hypertension, before the diagnosis of HF.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [260]
In the citing paper
“Given that diastolic heart disease develops early in T2D and the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of HF, the use of an ACE inhibitor or ARBs could be considered early in the treatment of hypertension, before the diagnosis of HF.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [260]
In the citing paper
“Two clinical trials studied the combinations of ACE inhibitors and ARBs and found no benefits on CVD or CKD, and the medication combination had higher adverse event rates (hyperkalemia and/or AKI) (87,88).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [88]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [85]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [85]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Clinical Physiology of Acid-Base and Electrolyte Disorders
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-2-176_8 · Cited by 1,156
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910
Research works printed but not linked: 2
- National Kidney Foundation, 2002, Am J Kidney Dis, 30, S1
- International Conference on Harmonisation, 1995, Fed Regist, 60, 11284
Cited by
Items 101–200 of 1,001
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s011 · Cited by 318
Hyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial
Agarwal, R., Joseph, A., Anker, S. D., Filippatos, G., Rossing, P., Ruilope, L. M., Pitt, B., Kolkhof, P., Scott, C., Lawatscheck, R., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021070942 · Cited by 262
Protective Factors and the Pathogenesis of Complications in Diabetes
Yu, M. G., Gordin, D., Fu, J., Park, K., Li, Q., & King, G. L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnad030 · Cited by 228
Treatment of Diabetic Kidney Disease: Current and Future
Yamazaki, T., Mimura, I., Tanaka, T., & Nangaku, M. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0217 · Cited by 237
Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
Lambers Heerspink, H. J., Kröpelin, T. F., Hoekman, J., & de Zeeuw, D. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070688 · Cited by 242
Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease
Coca, S. G., Nadkarni, G. N., Huang, Y., Moledina, D. G., Rao, V., Zhang, J., Ferket, B., Crowley, S. T., Fried, L. F., & Parikh, C. R. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016101101 · Cited by 239
Self-citationDrawz, P., & Rahman, M. (2015) · Annals of Internal Medicine · doi:10.7326/aitc201506020 · Cited by 231
Herrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M. J., Baigent, C., et al. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy090 · Cited by 237
Drug-induced impairment of renal function
Shirali, A., & Pazhayattil, G. S. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s39747 · Cited by 227
Romagnani, P., Agarwal, R., Chan, J. C. N., Levin, A., Kalyesubula, R., Karam, S., Nangaku, M., Rodríguez-Iturbe, B., & Anders, H.-J. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00589-9 · Cited by 184
Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes
Bai, L., Gao, J., Wei, F., Zhao, J., Wang, D., & Wei, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00423 · Cited by 229
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 226
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 225
9. Cardiovascular Disease and Risk Management
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s012 · Cited by 223
Navarro-González, J. F., Mora-Fernández, C., Muros de Fuentes, M., Chahin, J., Méndez, M. L., Gallego, E., Macía, M., del Castillo, N., Rivero, A., Getino, M. A., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014010012 · Cited by 221
Sarafidis, P., Ferro, C. J., Morales, E., Ortiz, A., Malyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J., Fouque, D., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy407 · Cited by 204
Currie, G., Taylor, A. H. M., Fujita, T., Ohtsu, H., Lindhardt, M., Rossing, P., Boesby, L., Edwards, N. C., Ferro, C. J., Townend, J. N., et al. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0337-0 · Cited by 214
Menne, J., Eulberg, D., Beyer, D., Baumann, M., Saudek, F., Valkusz, Z., Więcek, A., Haller, H., & for the Emapticap Study Group (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv459 · Cited by 201
Jha, J. C., Ho, F., Dan, C., & Jandeleit-Dahm, K. (2018) · Clinical Science · doi:10.1042/cs20171459 · Cited by 205
Diabetic Kidney Disease: Challenges, Advances, and Opportunities
Chen, Y., Lee, K., Ni, Z., & He, J. C. (2020) · Kidney Diseases · doi:10.1159/000506634 · Cited by 200
Diabetic kidney disease: from physiology to therapeutics
Mora‐Fernández, C., Domínguez‐Pimentel, V., de Fuentes, M. M., Górriz, J. L., Martínez‐Castelao, A., & Navarro‐González, J. F. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.272328 · Cited by 194
Management of hyperkalaemia in chronic kidney disease
Kovesdy, C. P. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.168 · Cited by 201
Diabetic Nephropathy: a Tangled Web to Unweave
Magee, C., Grieve, D. J., Watson, C. J., & Brazil, D. P. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6755-9 · Cited by 190
Zhang, Y., He, D., Zhang, W., Xing, Y., Guo, Y., Wang, F., Jia, J., Yan, T., Liu, Y., & Lin, S. (2020) · Drugs · doi:10.1007/s40265-020-01290-3 · Cited by 186
Bonner, R., Albajrami, O., Hudspeth, J., & Upadhyay, A. (2020) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2020.08.004 · Cited by 177
The double challenge of resistant hypertension and chronic kidney disease
Rossignol, P., Massy, Z. A., Azizi, M., Bakris, G., Ritz, E., Covic, A., Goldsmith, D., Heine, G. H., Jager, K. J., Kanbay, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00418-3 · Cited by 194
Mitochondrial Hormesis and Diabetic Complications
Sharma, K. (2015) · Diabetes · doi:10.2337/db14-0874 · Cited by 193
The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
Muskiet, M. H. A., Smits, M. M., Morsink, L. M., & Diamant, M. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.272 · Cited by 181
Update on diagnosis, pathophysiology, and management of diabetic kidney disease
Sugahara, M., Pak, W. L. W., Tanaka, T., Tang, S. C. W., & Nangaku, M. (2021) · Nephrology · doi:10.1111/nep.13860 · Cited by 171
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Nowack, C., Kolkhof, P., Ferreira, A. C., Schloemer, P., Filippatos, G., et al. (2019) · American Journal of Nephrology · doi:10.1159/000503713 · Cited by 184
Bandak, G., Sang, Y., Gasparini, A., Chang, A. R., Ballew, S. H., Evans, M., Arnlov, J., Lund, L. H., Inker, L. A., Coresh, J., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005428 · Cited by 181
“Although many of the risk characteristics have been previously identified, an existing risk score did not incorporate sex or potassium, one of the strongest observed risk factors.(24,25,29) In our study, male sex was also a risk factor for the development of hyperkalemia, potentially because of lower intake of potassi…”
The glycocalyx—linking albuminuria with renal and cardiovascular disease
Rabelink, T. J., & de Zeeuw, D. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.162 · Cited by 178
Interactions between kidney disease and diabetes: dangerous liaisons
Pecoits-Filho, R., Abensur, H., Betônico, C. C. R., Machado, A. D., Parente, E. B., Queiroz, M., Salles, J. E. N., Titan, S., & Vencio, S. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0159-z · Cited by 171
Diabetes mellitus and stroke: A clinical update
Tun, N. N., Arunagirinathan, G., Munshi, S. K., & Pappachan, J. M. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i6.235 · Cited by 177
Targeting inflammation in diabetic nephropathy: a tale of hope
Moreno, J. A., Gomez-Guerrero, C., Mas, S., Sanz, A. B., Lorenzo, O., Ruiz-Ortega, M., Opazo, L., Mezzano, S., & Egido, J. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1538352 · Cited by 170
Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View
Lambers Heerspink, H. J., & Gansevoort, R. T. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11511114 · Cited by 168
Therapeutic approaches to diabetic nephropathy—beyond the RAS
Fernandez-Fernandez, B., Ortiz, A., Gomez-Guerrero, C., & Egido, J. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.74 · Cited by 170
Navaneethan, S. D., Zoungas, S., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Liew, A., Michos, E. D., Olowu, W. A., Sadusky, T., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m20-5938 · Cited by 163
Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)
Wang, J. (2025) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2025.01.008 · Cited by 196
Albasri, A., Hattle, M., Koshiaris, C., Dunnigan, A., Paxton, B., Fox, S. E., Smith, M., Archer, L., Levis, B., Payne, R. A., et al. (2021) · BMJ · doi:10.1136/bmj.n189 · Cited by 163
Kim, H.-L., Lee, E. M., Ahn, S. Y., Kim, K.-I., Kim, H. C., Kim, J. H., Lee, H.-Y., Lee, J. H., Park, J.-M., Cho, E. J., et al. (2023) · Clinical Hypertension · doi:10.1186/s40885-023-00234-9 · Cited by 164
The New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications
Lytvyn, Y., Bjornstad, P., van Raalte, D. H., Heerspink, H. L., & Cherney, D. Z. I. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz010 · Cited by 165
Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease
Lazich, I., & Bakris, G. L. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.04.008 · Cited by 164
Škrtić, M., Yang, G. K., Perkins, B. A., Soleymanlou, N., Lytvyn, Y., von Eynatten, M., Woerle, H. J., Johansen, O. E., Broedl, U. C., Hach, T., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3396-4 · Cited by 159
Executive summary for the 2015 Annual Data Report of the China Kidney Disease Network (CK-NET)
Wang, F., Yang, C., Long, J., Zhao, X., Tang, W., Zhang, D., Bai, K., Su, Z., Gao, B., Chu, H. A., et al. (2019) · Kidney International · doi:10.1016/j.kint.2018.11.011 · Cited by 168
Immunologic Effects of the Renin-Angiotensin System
Crowley, S. D., & Rudemiller, N. P. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016101066 · Cited by 153
Škrtić, M., & Cherney, D. Z. I. (2015) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0000000000000084 · Cited by 148
LRG1 Promotes Diabetic Kidney Disease Progression by Enhancing TGF-β–Induced Angiogenesis
Hong, Q., Zhang, L., Fu, J., Verghese, D. A., Chauhan, K., Nadkarni, G. N., Li, Z., Ju, W., Kretzler, M., Cai, G., et al. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018060599 · Cited by 164
Schrauben, S. J., Shou, H., Zhang, X., Anderson, A. H., Bonventre, J. V., Chen, J., Coca, S. G., Furth, S. L., Greenberg, J. H., Gutiérrez, O. M., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020040487 · Cited by 164
Capítulo 1 - Conceituação, Epidemiologia e Prevenção Primária
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160151 · Cited by 228
A perspective on chronic kidney disease progression
Zhong, J., Yang, H., & Fogo, A. B. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00266.2016 · Cited by 169
Novel RAAS agonists and antagonists: clinical applications and controversies
Romero, C. A., Orias, M., & Weir, M. R. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.6 · Cited by 147
Hyperkalemia and Hypokalemia in CKD: Prevalence, Risk Factors, and Clinical Outcomes
Gilligan, S., & Raphael, K. L. (2017) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.06.004 · Cited by 146
Prevention of Microvascular Complications of Diabetes
Crasto, W., Patel, V., Davies, M. J., & Khunti, K. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.05.005 · Cited by 167
Perkovic, V., Agarwal, R., Fioretto, P., Hemmelgarn, B. R., Levin, A., Thomas, M. C., Wanner, C., Kasiske, B. L., Wheeler, D. C., Groop, P.-H., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.010 · Cited by 136
Zhang, Y., Le, X., Zheng, S., Zhang, K., He, J., Liu, M., Tu, C., Rao, W., Du, H., Ouyang, Y., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02855-7 · Cited by 148
Whaley‐Connell, A. T., & Sowers, J. R. (2017) · Kidney International · doi:10.1016/j.kint.2016.12.034 · Cited by 143
Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD
Sinha, A. D., & Agarwal, R. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04330418 · Cited by 135
Bianchi, S., Aucella, F., Nicola, L. D., Genovesi, S., Paoletti, E., & Regolisti, G. (2019) · Journal of Nephrology · doi:10.1007/s40620-019-00617-y · Cited by 145
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Mende, C. W. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01994-2 · Cited by 147
Bhandari, S., Ives, N., Brettell, E. A., Valente, M., Cockwell, P., Topham, P. S., Cleland, J. G., Khwaja, A., & El Nahas, M. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv346 · Cited by 127
Obesity‐related glomerulopathy: Current approaches and future perspectives
Martínez‐Montoro, J. I., Morales, E., Cornejo-Pareja, I. M., Tinahones, F. J., & Fernández‐García, J. C. (2022) · Obesity Reviews · doi:10.1111/obr.13450 · Cited by 145
Ando, K., Ohtsu, H., Uchida, S., Kaname, S., Arakawa, Y., & Fujita, T. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70194-9 · Cited by 134
Sasso, F. C., Pafundi, P. C., Simeon, V., De Nicola, L., Chiodini, P., Galiero, R., Rinaldi, L., Nevola, R., Salvatore, T., Sardu, C., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01343-1 · Cited by 129
Combination therapy for kidney disease in people with diabetes mellitus
van Raalte, D. H., Bjornstad, P., Cherney, D. Z. I., de Boer, I. H., Fioretto, P., Gordin, D., Persson, F., Rosas, S. E., Rossing, P., Schaub, J. A., et al. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00827-z · Cited by 127
Targeting inflammation: New therapeutic approaches in chronic kidney disease (CKD)
Impellizzeri, D., Esposito, E., Attley, J., & Cuzzocrea, S. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.02.007 · Cited by 136
Neuen, B. L., Oshima, M., Perkovic, V., Agarwal, R., Arnott, C., Bakris, G., Cannon, C. P., Charytan, D. M., Edwards, R., Górriz, J. L., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab497 · Cited by 123
Akbari, A., Clase, C. M., Acott, P., Battistella, M., Bello, A. K., Feltmate, P., Grill, A. K., Karsanji, M., Komenda, P. V. J., Madore, F., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.10.013 · Cited by 149
Herrington, W. G., Judge, P. K., Grams, M. E., & Wanner, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01942-7 · Cited by 150
Agarwal, R., Pitt, B., Palmer, B. F., Kovesdy, C. P., Burgess, E. D., Filippatos, G. S., Małyszko, J., Ruilope, L. M., Rossignol, P., Rossing, P. R., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac234 · Cited by 124
China Kidney Disease Network (CK-NET) 2015 Annual Data Report
Zhang, L., Zhao, M., Zuo, L., Wang, Y., Yu, F., Zhang, H., Wang, H., Bai, K., Chen, R., Chu, H. A., et al. (2019) · Kidney International Supplements · doi:10.1016/j.kisu.2018.11.001 · Cited by 125
Interplay of Vitamin D, Erythropoiesis, and the Renin-Angiotensin System
Santoro, D., Caccamo, D., Lucisano, S., Buemi, M., Šebeková, K., Teta, D., & Nicola, L. D. (2015) · BioMed Research International · doi:10.1155/2015/145828 · Cited by 129
Review of Herbal Traditional Chinese Medicine for the Treatment of Diabetic Nephropathy
Sun, G., Li, C., Cui, W., Guo, Q.-Y., Dong, C., Zou, H.-B., Liu, S., Dong, W., & Miao, L. (2015) · Journal of Diabetes Research · doi:10.1155/2016/5749857 · Cited by 115
Mansfield, K. E., Nitsch, D., Smeeth, L. L., Bhaskaran, K., & Tomlinson, L. A. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012690 · Cited by 114
Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression
Wang, N., & Zhang, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063086 · Cited by 139
Neprilysin inhibition in chronic kidney disease
Judge, P., Haynes, R., Landray, M., & Baigent, C. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu269 · Cited by 118
Diabetic nephropathy: where are we on the journey from pathophysiology to treatment?
Gallagher, H., & Suckling, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12630 · Cited by 119
Chronic Kidney Disease in Diabetes
McFarlane, P. A., Cherney, D. Z. I., Gilbert, R. E., & Senior, P. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.11.004 · Cited by 143
Novel Therapies for Diabetic Kidney Disease
Alicic, R. Z., & Tuttle, K. R. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.01.007 · Cited by 113
Catalá-López, F., Macías Saint-Gerons, D., González-Bermejo, D., Rosano, G. M., Davis, B. R., Ridao, M., Zaragoza, A., Montero-Corominas, D., Tobías, A., de la Fuente-Honrubia, C., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001971 · Cited by 109
“decades, the composite endpoints of major cardiovascular outcome and progression of renal disease have become standard outcomes of large randomized trials [13,40,41,75].”
BackgroundAgarwal, R., Tu, W., Farjat, A. E., Farag, Y. M. K., Toto, R., Kaul, S., Lawatscheck, R., Rohwedder, K., Ruilope, L. M., Rossing, P., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m23-1023 · Cited by 109
Self-citationDiabetic nephropathy: landmark clinical trials and tribulations
Chan, G. C. W., & Tang, S. C. W. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu411 · Cited by 117
Angiotensin-converting Enzyme Inhibitor-induced Angioedema
Bezalel, S. R., Mahlab‐Guri, K., Asher, I., Werner, B., & Sthoeger, Z. M. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.07.011 · Cited by 116
‘Progressive diabetic nephropathy. How useful is microalbuminuria?: contra’
MacIsaac, R. J., Ekinci, E. I., & Jerums, G. (2014) · Kidney International · doi:10.1038/ki.2014.98 · Cited by 111
New pharmacological strategies for protecting kidney function in type 2 diabetes
Muskiet, M. H. A., Wheeler, D. C., & Heerspink, H. J. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30263-8 · Cited by 107
Comprehensive approach to diabetic nephropathy
Satirapoj, B., & Adler, S. G. (2014) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2014.08.001 · Cited by 123
Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy
Ilyas, Z., Chaiban, J. T., & Krikorian, A. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-017-9422-3 · Cited by 115
Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report
Weir, M. R., Lakkis, J. I., Jaar, B. G., Rocco, M. V., Choi, M. J., Kramer, H., & Ku, E. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.06.010 · Cited by 110
Clinical Challenges in Diagnosis and Management of Diabetic Kidney Disease
Stanton, R. C. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.10.050 · Cited by 115
Agarwal, R., Anker, S. D., Bakris, G., Filippatos, G., Pitt, B., Rossing, P., Ruilope, L., Gebel, M., Kolkhof, P., Nowack, C., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa294 · Cited by 103
Kovesdy, C. P., Appel, L. J., Grams, M. E., Gutekunst, L., McCullough, P. A., Palmer, B. F., Pitt, B., Sica, D. A., & Townsend, R. R. (2017) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2017.09.011 · Cited by 109
Self-citationAlexandrou, M.-E., Papagianni, A., Tsapas, A., Loutradis, C., Boutou, A., Piperidou, A., Papadopoulou, D., Ruilope, L., Bakris, G., & Sarafidis, P. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002187 · Cited by 101
2019 Chinese guideline for the management of hypertension in the elderly.
Hua, Q., Fan, L. H., & Li, J. (2019) · PubMed Central · doi:10.11909/j.issn.1671-5411.2019.02.001 · Cited by 113
Advances in the management of chronic kidney disease
Chen, T. K., Hoenig, M. P., Nitsch, D., & Grams, M. E. (2023) · BMJ · doi:10.1136/bmj-2022-074216 · Cited by 122
Kovesdy, C. P., Appel, L. J., Grams, M. E., Gutekunst, L., McCullough, P. A., Palmer, B. F., Pitt, B., Sica, D. A., & Townsend, R. R. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.09.003 · Cited by 100
Self-citationMosterd, C. M., Kanbay, M., van den Born, B. H., van Raalte, D. H., & Rampanelli, E. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101484 · Cited by 104
Bakris, G. L., Ruilope, L. M., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Fried, L. P., Roy‐Chaudhury, P., Sarafidis, P. A., Ahlers, C., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.08.040 · Cited by 102
Self-citationde Sousa, A. G. P., Cabral, J. V., El-Feghaly, W. B., sousa, L. K. L., & Nunes, A. B. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i5.101 · Cited by 94
The Role of Mitochondria in Diabetic Kidney Disease
Hallan, S. I., & Sharma, K. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0748-0 · Cited by 98
Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?
Gregg, L. P., & Hedayati, S. S. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.12.007 · Cited by 91
Metadata
- Authors
- Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., Reilly, R. F., Seliger, S. L., Warren, S. R., Watnick, S., Peduzzi, P., & Guarino, P.
- Affiliations
- Boston University (US)
- Loyola University Medical Center (US)
- VA Connecticut Healthcare System (US)
- University of New Mexico (US)
- University of Arizona (US)
- Ascension (US)
- University of Pittsburgh (US)
- VA North Texas Health Care System (US)
- University of Maryland, Baltimore (US)
- Portland VA Medical Center (US)
- Yale University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-11-14
- Volume
- 369
- Issue
- 20
- Pages
- 1892-1903
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2162368776
- Semantic Scholar
- 7e191f2ee9fe17b31623d78bf58b03d157e94654
- Cited by
- 1,169
- References
- 19
- Citations by year
- 2026: 32 · 2025: 56 · 2024: 67 · 2023: 95 · 2022: 75 · 2021: 102 · 2020: 89 · 2019: 105 · 2018: 88 · 2017: 98 · 2016: 104 · 2015: 123 · 2014: 122 · 2013: 9
- FWCI
- 90.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- diabetic nephropathy, losartan, lisinopril, ACE inhibitors, angiotensin receptor blockers, type 2 diabetes, estimated glomerular filtration rate decline, end-stage renal disease, albuminuria, hyperkalemia, acute kidney injury, drug safety, early trial termination, cardiovascular events, mortality, proteinuria, kidney disease progression
- MeSH terms
- Adult, Angiotensin-Converting Enzyme Inhibitors, Diabetic Nephropathies, Double-Blind Method, Drug Therapy, Combination, Female, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic, Male, Middle Aged, Lisinopril, Losartan, Angiotensin II Type 1 Receptor Blockers, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.